Most of the exciting work being done right now in cancer immunotherapy is centred on highly targeted approaches that aim to activate only the most necessary immune responses to eliminate a
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh